By August 15, 2026: Billing team must identify which Medicare Administrative Contractor (MAC) jurisdiction applies to your practice location and obtain the corresponding LCD documents referenced in the policy (MolDX panels, NCD 90.2, and jurisdiction-specific LCAs). Update billing system prior authorization rules, billing software templates, and claim submission protocols to align with the specific MAC's requirements for genetic testing. Map current genetic testing procedures to appropriate CPT/HCPCS codes per the referenced MolDX billing and coding guidance. Train providers and front-desk staff on required documentation for medical necessity (disease symptoms, diagnosis/rule-out indication, or monitoring of known cancer). Before 09/01/2026: Test billing system changes in sandbox environment. Verify that claims for comprehensive genomic profiling (e.g., FoundationOne Heme, Neogenomics, Tempus xT Heme), multigene panels, and single-gene tests (JAK2 V617F, FLT3, NPM1, TP53, IDH1, IDH2, ASXL1, BTK, CCND1, CEBPA, CSF3R, CXCR4, FGFR1, KIT, KMT2A, MYD88, NRAS, PDGFRA, PLCG2, RUNX1, SF3B1, SRSF2, U2AF1, and others) will route to correct MAC LCD. Effective 09/01/2026: Begin enforcing new policy requirements. Claims submitted without proper documentation of medical necessity or that do not comply with MAC-specific LCD requirements will be denied. Identify your practice's MAC jurisdiction from the geographic table in the policy and request the applicable LCD documents immediately.